A Study in Non-Small Cell Lung Cancer
Purpose
A study to create control arms using current and future information in patients with lung cancer.
Condition
- Non Small Cell Lung Cancer
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- > 18 years of age at the time of informed consent 2. Pathologically confirmed NSCLC 3 .ECOG Performance of >1 and fit for further systemic therapy on a NCCN approved regimen (within 4 weeks prior or 14 days after starting second line therapy) 4. Life expectancy of more than 3 months 5. Able to understand and sign informed consent *see protocol for cohort specific inclusion criteria*
Exclusion Criteria
- Unable to provide informed consent 2. Actively on a clinical trial of an investigational agent 3. Non protocol compliant baseline imaging scan (modality/coverage) prior to index date in patients included after the second or third line therapy has been initiated *see protocol for cohort specific exclusion criteria* -
Study Design
- Phase
- Study Type
- Observational [Patient Registry]
- Observational Model
- Cohort
- Time Perspective
- Prospective
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
| Cohort 1 | Patients starting first line pembrolizumab or pembrolizumab in combination with a platinum doublet | |
| Cohort 2 | Patients with KRASG12D mutation starting first or later line of therapy | |
| Cohort 3 | Patients planned to have second line docetaxel or docetaxel in combination with ramucirumab with tumor without alterations in KRAS, EGFR, ALK, or ROS1 | |
| Cohort 4 | Patients with PD-L1 > 50% treated with single agent immuno-oncology therapy (IO) or dual IO agents as first line treatment. | |
| Cohort 5 | Patients with PD-L1 < 50% without alterations in KRAS, EGFR, ALK, or ROS1 | |
| Cohort 6 | Patients with documented KRAS G12C mutation | |
| Cohort 7 | Patients with non-G12C and non-G12D KRAS mutations | |
| Cohort 8 | Patients with EGFR mutations with prior treatment with osimertinib in combination with chemotherapy or lazertinib in combination with amivantamab | |
| Cohort 9 | Patients initiating single agent docetaxel or docetaxel and ramucirumab as third line of therapy |
Recruiting Locations
Pacific Cancer Care
Monterey, California 93940
Monterey, California 93940
Bayhealth Medical Center, Kent Campus
Dover, Delaware 19901
Dover, Delaware 19901
Bayhealth Medical Center- Sussex Campus
Milford, Delaware 19963
Milford, Delaware 19963
Northwest Oncology and Hematology
Barrington, Illinois 60010
Barrington, Illinois 60010
Northwest Oncology and Hematology
Elk Grove, Illinois 60008
Elk Grove, Illinois 60008
Northwest Oncology and Hematology
Hoffman Estates, Illinois 60169
Hoffman Estates, Illinois 60169
Northwest Oncology and Hematology
Rolling Meadows, Illinois 60008
Rolling Meadows, Illinois 60008
Oncology Consultants
Houston, Texas 77030
Houston, Texas 77030
More Details
- Status
- Recruiting
- Sponsor
- N-Power Medicine